title: Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
abstract: OBJECTIVE
  The aim of this study was to compare the efficacy and safety of moxifloxacin with that of amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults.
  
  
  METHODS
  Five hundred seventy-five patients from Latin American countries were randomized to receive oral moxifloxacin 400 mg once daily for 7 days, or oral amoxicillin/clavulanate 500/125 mg 3 times daily for 10 days, in a prospective, open study.
  
  
  RESULTS
  At the test-of-cure visit (7-14 days after the end of therapy), the clinical success rate in the moxifloxacin group was 93.4% similar to that in the amoxicillin/clavulanate group (92.7%). Documented bacteriological eradication plus presumed eradication rates in the moxifloxacin (96.5%) and the amoxicillin/clavulanate (96.7%) groups were also similar. Drug-related adverse events were recorded in 32.2% of patients in the moxifloxacin group and 29.7% in the amoxicillin/clavulanate group. Patient discontinuation in the trial due to adverse events occurred for 10 patients in the moxifloxacin group and 6 in the amoxicillin/clavulanate group.
  
  
  CONCLUSIONS
  Overall, in terms of clinical and bacteriological response, moxifloxacin was equivalent to amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults.
authors.affiliation: Hospital General Dr. Manuel Gea González, Mexico City, Mexico.
authors.forename: José R
authors.initials: JR
authors.lastname: Arrieta
authors.forename: Alejandro S
authors.initials: AS
authors.lastname: Galgano
authors.forename: Eulalia
authors.initials: E
authors.lastname: Sakano
authors.forename: Ximena
authors.initials: X
authors.lastname: Fonseca
authors.forename: Carlos F
authors.initials: CF
authors.lastname: Amábile-Cuevas
authors.forename: Gerardo
authors.initials: G
authors.lastname: Hernández-Oliva
authors.forename: Raul
authors.initials: R
authors.lastname: Vivar
authors.forename: Gerardo
authors.initials: G
authors.lastname: González
authors.forename: Arturo
authors.initials: A
authors.lastname: Torres
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011446:Prospective Studies; D011804:Quinolines / Q000627:therapeutic use*; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D019980:Amoxicillin-Potassium Clavulanate Combination; D000077266:Moxifloxacin